H. Lundbeck A/S
May 8, 2018

Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS


In connection with the financial report, Lundbeck's interim CEO and CFO, Anders Götzsche said:
"I am really pleased with the performance, which shows that we have a product range that provides a unique opportunity to improve the treatment of people with psychiatric and neurological disorders. We have realized solid revenue growth even considering headwind from exchange rates and generic erosion and continue the strong improvement in profitability. I am also pleased that we have fortified the R&D pipeline by the inclusion of foliglurax, currently in phase II clinical development. It is a good start to the year."  

DKK million Q1 2018  Q1 2017 Growth
Reported Revenue 4,585 4,211 9%
Reported EBIT 1,656 1,011 64%
Reported EPS 6.03 2.97 103%
Reported EBIT margin 36.1% 24.0% -
Core Revenue* 4,585 4,211 9%
Core EBIT* 1,818 1,213 50%
Core EPS* 6.79 3.90 74%
Core EBIT margin* 39.6% 28.8% -

       *For definition of the measures "Core Revenue", "Core EBIT" and "Core EPS", see note 8 Core reporting